NVG-2089

Phase 2Small molecule

NNuvig Therapeutics, Inc.

NVG-2089 is one of 3 small molecule programs targeting Immune Thrombocytopenia (ITP). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune Thrombocytopenia (ITP)Recruiting

Immune Thrombocytopenia (ITP)Phase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Immune Thrombocytopenia (ITP)

#DrugCompanyPhaseTrials

Jaypirca

Eli Lilly

Preclinical

1 2

Vyvgart

Argenx

Preclinical

1 3

NVG-2089

NNuvig Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Immune Thrombocytopenia (ITP)

NCT07095127

Clinical

Trials by Indication[1]

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Terminated·NNuvig Therapeutics, Inc.·Phase 2·NCT07027111·14 enrolled

Immune Thrombocytopenia (ITP)1 trial

An Open-Label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants With Immune Thrombocytopenia

Recruiting·NNuvig Therapeutics, Inc.·Phase 2·NCT07095127·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NVG-2089. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NVG-2089 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NVG-2089. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nuvig Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNuvig Therapeutics, Inc.

NVG-2089

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Immune Thrombocytopenia (ITP)1 trial

References

Drug Info

Quick Facts

Related News